1. Home
  2. SPOK vs ALLO Comparison

SPOK vs ALLO Comparison

Compare SPOK & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

HOLD

Current Price

$13.09

Market Cap

267.8M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPOK
ALLO
Founded
2004
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.8M
252.9M
IPO Year
1992
2018

Fundamental Metrics

Financial Performance
Metric
SPOK
ALLO
Price
$13.09
$1.62
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.27
AVG Volume (30 Days)
164.4K
4.1M
Earning Date
02-25-2026
11-06-2025
Dividend Yield
9.45%
N/A
EPS Growth
12.68
N/A
EPS
0.80
N/A
Revenue
$139,739,000.00
N/A
Revenue This Year
$4.11
N/A
Revenue Next Year
$2.63
$100.00
P/E Ratio
$16.53
N/A
Revenue Growth
1.47
N/A
52 Week Low
$12.26
$0.86
52 Week High
$19.31
$3.78

Technical Indicators

Market Signals
Indicator
SPOK
ALLO
Relative Strength Index (RSI) 48.07 59.70
Support Level $12.86 $1.62
Resistance Level $13.35 $1.88
Average True Range (ATR) 0.25 0.11
MACD 0.04 0.02
Stochastic Oscillator 55.55 56.41

Price Performance

Historical Comparison
SPOK
ALLO

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: